Opinions
Jim Cramer - Mad Money
Osmotica Pharmaceuticals
OSMT-Q
DON'T BUY
Sep 11, 2020
A tiny company and speculative. Some months ago, they had a tired, but profitable portfolio of generic and profitable drugs that produced a stream of cash. They invested that cash to treat droopy eyelid, with a goal to be a less-generic drug company and more branded. Then they tested an MS-related drug, but shelved it which hurt the stock. Two months, the FDA approved the droopy eyelid drug which pushed the stock higher. Then they made a secondary offering which didn't meet demand and the stock pulled back.
$4.960
Stock price when the opinion was issued
Pharma & Healthcare
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
DON'T BUY
A tiny company and speculative. Some months ago, they had a tired, but profitable portfolio of generic and profitable drugs that produced a stream of cash. They invested that cash to treat droopy eyelid, with a goal to be a less-generic drug company and more branded. Then they tested an MS-related drug, but shelved it which hurt the stock. Two months, the FDA approved the droopy eyelid drug which pushed the stock higher. Then they made a secondary offering which didn't meet demand and the stock pulled back.
Pharma & Healthcare
Advertising